A molecular immunology approach to antibody humanization and functional optimization

Amino acid substitution matrices from protein blocks.

1992 • 5,998 citations

Sequences of proteins of immunological interest

1984 • 3,427 citations

Entrez Gene: gene-centered information at NCBI

2010 • 2,133 citations

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1986 • 1,356 citations

Potent antibody therapeutics by design

2006 • 1,076 citations

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

1984 • 1,002 citations

Engineered antibody Fc variants with enhanced effector function

2006 • 753 citations

Entrez Gene: gene-centered information at NCBI

2004 • 719 citations

Immunogenicity of engineered antibodies

2005 • 587 citations

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.

1990 • 401 citations

Sequence Variability Analysis of Human Class I and Class II MHC Molecules: Functional and Structural Correlates of Amino Acid Polymorphisms

2003 • 375 citations

Biophysical Properties of Human Antibody Variable Domains

2002 • 321 citations

Antibody humanization: a case of the ‘Emperor’s new clothes’?

2000 • 252 citations

Strategies for selection of antibodies by phage display

1998 • 245 citations

Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modeling and Analysis Tool

2001 • 224 citations

Ontology for immunogenetics: the IMGT-ONTOLOGY

1999 • 223 citations

Molecular Biology of B Cells

2015 • 188 citations

Rational design and engineering of therapeutic proteins

2003 • 187 citations

Minimizing the immunogenicity of protein therapeutics

2004 • 167 citations

Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity

2005 • 165 citations

Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma

1993 • 144 citations

Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33.

2001 • 143 citations

Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A.

1987 • 137 citations

Economic aspects of commercial manufacture of biopharmaceuticals

2004 • 137 citations

“Superhumanized” Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD28

2002 • 93 citations

Use of human germline genes in a CDR homology-based approach to antibody humanization

2005 • 91 citations

Molecular Biology of B Cells

2004 • 86 citations

Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity

2005 • 86 citations

CD30-mediated cell cycle arrest associated with induced expression of p21CIP1/WAF1 in the anaplastic large cell lymphoma cell line Karpas 299

2001 • 70 citations

Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation.

1993 • 67 citations

Production of human antibody repertoires in transgenic mice

1997 • 65 citations

[5] Humanization of monoclonal antibodies

1991 • 48 citations

Coordinate-based cluster analysis

1995 • 40 citations

Rationally Engineered Proteins or Antibodies with Absent or Reduced Immunogenicity

2002 • 35 citations

Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody

2002 • 33 citations

Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligand.

2003 • 16 citations